Abstract
Although still unproved, the therapeutic potential of PAF antagonists for the treatment of diseases with an inflammatory component has been recognized for at least fifteen years. Over this period numerous antagonists encompassing an array of structural classes have been discovered that exhibit moderate to excellent intrinsic potency and are generally effective in animal models of PAF-mediated diseases1,2. However, PAF antagonists for the most part have not proven effective in human disease3–7. To date, the most encouraging results come from the recent report that WEB-2086, when given at higher doses than studied previously to patients with mild to moderate asthma, resulted in improvement in lung function parameters8. In sepsis studies, improvement in survival of a subset of gram-negative patients receiving BN-52021 has also been reported9. A trend toward reduced mortality was also observed in follow-up studies, although the effect did not reach statistical significance10. These modest improvements observed in asthma and the suggestion of a positive effect in sepsis suggest that the currently available antagonists may lack sufficient potency to be optimally effective and support the need for more potent antagonists for human studies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Koltai, M., D. Hosford, R. Guinot, A. Esanu, and P. Braquet. “Platelet activating factor. A review of its effects, antagonists and possible future clinical implications.” Drugs 42 (1991): 9–29, 174–204.
Summers, J.B., and D.H. Albert. “Platelet Activating Factor Antagonists.” In Advances in Pharmacology, edited by J.T. August, M.W. Anders, F. Murad and J. Coyle, 67–168. New York: Academic Press, 1995.
Freitag, A., R.M. Watson, G. Matsos, C. Eastwood, and P.M. O’Byrne. “Effect of a PAF antagonist WEB-2086, on allergen induced asthmatic response.” Thorax 48 (1993): 594–598.
Wilkens, J.H., H. Wilkens, J. Uffmann, J. Boyers, H. Fabel, and J.C. Frolich. “Effects of a PAF antagonist (BN-52063) on bronchoconstriciton and platelet activation during exercise induced asthma.” Br. J. Clin. Pharmacol. 29, no. 1 (1990): 85–91.
Kuitert, L.M., K.P. Hui, S. Uthayarkumar, W. Burke, A.C. Newland, S. Uden, and N.C. Barnes. “Effect of the platelet-activating factor antagonist UK-74,505 on the early and late response to allergen.” Am. Rev. Respir. Dis. 147 (1993): 82–86.
Bel, E.H., M. De Smet, T.H. Rossing, M.C. Timmers, J.H. Dijkman, and P.J. Sterk. “The effect of a specific oral PAF-antagonist, MK-287, on antigen-induced early and late asthmatic reactions in man.” Amer. Rev. Resp. Dis$1143, no. 4 part 2 (1991): A811.
Dermarkarian, R.M., E. Israel, M.A. Rosenberg, A. Jansen, M.R. Danzig, J. Fourre, and J.M. Drazen. “The effect of Sch-37370, a dual PAF and histamine antagonist, on the bronchoconstriction induced in asthmatics by cold, dry air isocapnic hyperventialation.” Am. Rev. Respir. Dis$1143, no. 4, part 2 (1991): A812.
Tamura, G., T. Takishima, S. Mue, S. Makino, K. Itoh, T. Miyamoto, T. Shida, and S Nakajima. “Effectiveness of a Potent Platelet Activating Factor Antagonist, WEB-2086, on asthma: a multicentere, double-blind, placebo-controlled study.” Eur. Respir. J. 7 (1994): 752.
Dhainaut, J.F., A. Tenaillon, U.Y. Letulzo, B. Schlemmer, J.P. Solet, M. Wolff, L. Hillzapfel, F. Zeni, D. Dreyfuss, J.P. Mira, J.M. Crétien, V. Lavergne, and R. Guinot. “Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group.” Crit Care Med 22, no. 11 (1994): 1720–1728.
Dhainaut, J.F., A. Tenaillon, M. Hemmer, R. Damas, Y. Letulzo, P Radermacher, M.D. Schaller, J.P. Solet, M. Wolff, L. Holzapfel, F. Zeni, J. Motin, J.P. Mira, F. de Vathaire, J.M. Crétien, J. Marsais, M.L. Gourlay, and P. Guinot. “Confirming phase III clinical Trial to study the efficacy of a PAF antagonist, BN-52021, in reducing mortality of PTS with severe gram-negative sepsis.” American Journal of Respiratory and Critical Care Medicine 151, no. 4 (1995): A447.
Summers, J.B., D.H. Albert, S.K. Davidsen, R.G. Conway, J.H. Holms, T.J. Magoc, G. Luo, P. Tapang, D.A. Rhein, and G.W. Carter. “ABT-299, A Potent Antagonist of Platelet Activating Factor.” In Adv. Prost. Leuko. Res.: Raven, 1994.
Adamus, W.S., H.O. Heuer, C.J. Meade, and J.C. Schilling. “Inhibitory effects of the new PAF acether antagonist WEB-2086 on pharmacologie changes induced by PAF inhalation in human beings.” Clin. Pharmacol. Ther. 47 (1990): 456–462.
Mustard, JF, RL Kinlough-Rathbone, and MA Packham. “Platelet activation—an overview.” Agents Actions Suppl; 21 (1987): 23–36.
Davidsen, Steven K., James B. Summers, David J. Sweeny, James H. Holms, Daniel H. Albert, Richard G. Conway, and George W. Carter. “Active metabolites of indole pyrrolothiazole PAF antagonists.” J Med. Chem. (in press).
Herbert, J.M., G. Valett, A. Bemat, P. Savi, J.P. Maffrand, and G. Le Fur. “SR 27417, a highly potent, selective and long-acting antagonist of the PAF receptor.” Drugs Fut. 17, no. 11 (1992): 1011–1018.
Thompson, W.A., S. Coyle, K. Van Zee, H. Oldenburg, R. Trousdale, M. Rogy, D. Felsen, L. Moldawer, and S.F. Lowry. “The Metabolic Effects of PAF Antagonism in Endotoxemic Man.” Arch. Surg. 129 (1994): 72–79.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Albert, D.H. et al. (1996). Ex Vivo Inhibition of PAF-Induced β-Thromboglobulin Release in Man by ABT-299, a Potent PAF Antagonist. In: Nigam, S., Kunkel, G., Prescott, S.M. (eds) Platelet-Activating Factor and Related Lipid Mediators 2. Advances in Experimental Medicine and Biology, vol 416. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0179-8_61
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0179-8_61
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0181-1
Online ISBN: 978-1-4899-0179-8
eBook Packages: Springer Book Archive